Dr. Mihael Polymeropoulos, the co-founder and former CEO of Vanda Pharmaceuticals, joined Tucker Carlson on Thursday night to discuss the use of chloroquine in the treatment of coronavirus.
On Monday Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, reported that the anti-viral medication chloroquine is showing success in fighting the coronavirus.
** An Effective Treatment for Coronavirus (COVID-19)
Dr. Gregory Rigano, the co-author of the study, later went on with Laura Ingraham and then Tucker Carlson to discuss the results from the chloroquine study.
Dr. Rigano announced that their study found that COVID-19 patients who took hydroxy-chloroquine were found free of the disease in 6 days. The patients were testing negative for the coronavirus in six days!
Dr. Rigano also said taking choroquine could act as a preventative.
On Wednesday night Dr. Rigano told Tucker Carlson that a new peer-reviewed study out of France found that chloroquine had a 100% success rate in treating patients with coronavirus.
On @TuckerCarlson Tonight, Gregory Rigano, @RiganoESQ, a Stanford Univ. School of Medicine advisor announced a 100% cure rate in a controlled study done in France of 40 people with the #ChinaCoronaVirus with a malaria drug called #hydroxychloroquine. pic.twitter.com/m78oMhwxdi
— AZKayte (@AZKAYTE) March 19, 2020
Dr. Rigano also tweeted out his results:
UPDATE:
Full peer reviewed study has been released by Didier Raoult MD, PhD https://t.co/DzFTv13wYn.
After 6 days 100% of patients treated with HCQ + Azithromycin were virologically cured
p-value <.0001https://t.co/vttAIWbPwJ
— Gregory Rigano (@RiganoESQ) March 18, 2020
On Thursday night Dr. Mihael Polymeropoulos that not only is chloroquine successful in treating coronavirus but it acts as a prophylactic and may inhibit a person from catching the disease.
This is tremendous news!
The post MUST SEE: Chloroquine Already Used on Coronavirus in US — Study Shows 100% Success Rate — And May Act as Preventative to Virus (VIDEO) appeared first on The Gateway Pundit.